Cubit Diagnostics today announced it has closed its latest round of SAFE (Simple Agreement for Future Equity) financing. The proceeds will fund the company's next phase of work, centered on locking in design freeze for its molecular CT/NG/TV assay and expanding its immunoassay program.
CubitDx announced the appointment of Robert Bujarski and Mark Paiz to its Board of Directors, bringing deep experience across diagnostics, operations, and commercialization.
Cubit Diagnostics is proud to announce it was awarded $2.6 million through the National Institutes of Health (NIH) RADx® (Rapid Acceleration of Diagnostics) Tech program on December 2, 2024, marking a significant milestone in its mission to revolutionize point-of-care diagnostics with lab-level sensitivity and unmatched affordability.
Sponsored Research
Cubit is proud to work with select Universities to sponsor technology development and research projects. As part of this research, Cubit provides support for indirect costs up to a maximum rate of 20% of the total direct costs of the project. This maximum rate applies uniformly across all sponsored research projects.
Disclaimer
This website contains forward-looking statements regarding product development, performance targets, and future capabilities. Actual results may differ based on regulatory, technical, and clinical outcomes.
